In pharmaceutical technology Lactose and Hypromellose (HPMC) are well known excipients and commonly accepted. To overcome limited flow and segregation tendency of HPMC a wet granulation step is traditionally used for obtaining a processable tablet mass.

MEGGLE, as a specialist for Lactose excipients, has developed a new, innovative Lactose-HPMC co-processed material recently, which is commercially available under the brand name RetaLac®. RetaLac® consists of equal parts of α-lactose monohydrate and HPMC and was primarily designed to fulfill the requirements of direct compression: During compaction RetaLac® demonstrates superior functionality compared with the corresponding physical mixture. Co-processing has a significant impact on flowability, RetaLac® is free flowable in contrast to the corresponding physical mixture, which does not flow at all. Moreover segregation during processing is not possible, as the two co-processed excipients cannot be separated by mechanical methods. RetaLac® granules show a coarse texture with an highly structured surface, which can be a benefit for your content uniformity results.

In comparison to pure HPMC wettability of HPMC in a co-processed form together with Lactose (RetaLac®) is increased drastically, which might facilitate preparation of aqueous dispersions/solutions containing HPMC/Lactose or cleaning of equipment.

About MEGGLE:
MEGGLE AG, with its headquarters in the Bavarian city of Wasserburg (Germany), serves as a holding company for various business activities in the dairy industry and whey processing. MEGGLE has a proud history of more than 125 years in the dairy market.

The business group Excipients & Technology produces pharmaceutical excipients for direct compression, granulation, capsules, sachets, powder blends and dry powder inhalers. With its broad product portfolio, intelligent innovations and exceptional product quality, MEGGLE took a leading role in the global business of pharmaceutical excipients.
For more information please visit www.meggle-pharma.com

MEGGLE Gruppe Wasserburg
BG Excipients & Technology
Megglestraße 6 -12
83512 Wasserburg
Germany
Dr. Egmont Pfeifer
Phone +49 8071 73 476
Fax +49 8071 73 320
service.pharma@meggle.de
www.meggle-pharma.de